Rocket Pharmaceuticals Investors Advised to Contact Legal Team About Rights Before August 2025 Deadline

Attention Rocket Pharmaceuticals Investors

If you are a shareholder of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), it's crucial to act swiftly and contact The Gross Law Firm before August 11, 2025. This deadline is set for discussing your rights concerning recent allegations regarding the company’s statements and actions that may have affected your investment.

Class Period Details

The Gross Law Firm has issued a notification outlining that shareholders who acquired RCKT shares during the period of February 27, 2025, to May 26, 2025, should engage with the firm regarding potential lead plaintiff appointments in a class action lawsuit. While being a lead plaintiff is not a prerequisite to seeking recovery, this opportunity could provide significant legal recourse for affected investors.

Background of the Allegations

The crux of the allegations against Rocket Pharmaceuticals revolves around providing misleading information to investors. Reportedly, the company's management made overly optimistic statements while concealing critical facts about the clinical trial protocol for its RP-A501 treatment.

According to court documents, it was revealed that Rocket failed to disclose the risks associated with Serious Adverse Events (SAEs) that included patient fatalities. Furthermore, the company allegedly amended the trial protocol to include a new treatment regimen without adequately informing investors of these changes, leading to inflated share prices.

On May 27, 2025, after the adverse event revelations, Rocket Pharmaceuticals announced that the FDA had imposed a clinical hold on the RP-A501 Phase 2 pivotal study due to these incidents. This announcement resulted in a dramatic decline in the company’s stock price, plummeting nearly 37% in a matter of hours, from $6.27 per share to $2.33 per share.

Steps for Affected Shareholders

Shareholders are encouraged to promptly register with The Gross Law Firm to ensure they are informed of the progression of the case. Registration will grant access to portfolio monitoring software, giving regular updates on the lawsuit’s status. The deadline for interested parties to register as potential lead plaintiffs is August 11, 2025.

Why Choose The Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized class action law firm committed to protecting investor rights. They specialize in holding companies accountable for misleading practices and assure a diligent approach towards corporate governance. By participating in this case, shareholders can potentially reclaim losses incurred due to Rocket Pharmaceuticals' alleged false statements.

For further inquiries or to submit your information, visit The Gross Law Firm’s contact page or reach out directly via phone at (646) 453-8903.

This information should serve as an important alert to shareholders concerned about their rights and potential financial recovery. Don’t delay in getting the needed support to navigate this situation effectively.